Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 10 August 2015 | By Michael Mezher
On Friday, a New York Court sided with biopharmaceuticals maker Amarin in a suit against the US Food and Drug Administration (FDA) involving the off-label promotion of Vascepa.
Vascepa was initially approved by FDA to reduce triglyceride levels in adults with severe hypertriglyceridemia.
As reported by the FDA Law Blog, Amarin hoped to expand Vascepa's indication after learning that some doctors were using Vascepa off-label to treat patients with persistently high triglycerides. At the time, FDA agreed to accept a supplemental new drug application (sNDA) from Amarin with data from a new phase III study in patients with persistently high triglycerides, on the condition that Amarin would also study Vascepa's for use in reducing cardiovascular events.
However, after reviewing Amarin's sNDA, an FDA advisory committee voted against expanding Vascepa's indication, despite data showing the drug met an agreed upon endpoint, citing other trials that "cast doubt on the clinical benefit of triglyceride lowering."
Following the advisory committee vote, Amarin continued to include certain off-label use information in its promotional materials.
In May, Amarin sued FDA to prevent it from blocking its right to "commercial speech," which is protected under the First Amendment. In its suit, Amarin said it wanted to share the results of its study and other peer-reviewed studies on eicosapentaenoic acids (EPA) with doctors. Interestingly, before the case, FDA sent a letter stating it did not oppose the information Amarin intended to share, as long as it was made with the appropriate disclaimers and was truthful. In fact, much of Amarin's proposed communications were consistent with the agency's guidance on Distributing Scientific and Medical Publications on Unapproved New Uses – Recommended Practices.
For now, the court has issued an injunction, barring FDA from preventing Amarin from conducting "truthful and non-misleading speech promoting the off-label use of Vascepa." The court also cites the Caronia ruling, which established that "speech may not form the basis of a prosecution for misbranding."
It is still unclear how far-reaching the present ruling will be, as FDA did not plan to oppose much of Amarin's proposed promotional statements and Amarin had strong data from a phase III study to support its claims.
Court Order, FDA Law Blog
Tags: Off-label promotion, Amarin, Vascepa